Every listed Indian CDMO company covered here — Divi's Laboratories, Anthem, Blue Jet, Cohance, Gland, Neuland, Piramal Pharma, Sai Life, Shilpa, Syngene — against Laurus, on the same numbers from the same filings. Click a column to rank by it. Tick up to three and press Compare for the full side-by-side.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ₹274.0k Cr | 92.4× | 12.8% | 32.6% | 21.5% | 0.9× | 0.0× | 49.9% | |
| vs | 2Laurus | ₹126.3k Cr | 94.4× | 22.7% | 26.2% | 17.8% | 2.1× | 0.4× | 138.8% |
| 3 | ₹52.2k Cr | 45.6× | 14.5% | 25.3% | 14.9% | 1.2× | 0.0× | 66.9% | |
| 4 | ₹51.4k Cr | 87.0× | 15.2% | 39.3% | 29.6% | 0.9× | 0.0× | 31.4% | |
| 5 | ₹37.8k Cr | 103.1× | 29.4% | 28.8% | 19.2% | 1.8× | 0.1× | 93.5% | |
| 6 | ₹31.8k Cr | — | -3.1% | 10.4% | 1.2% | — | 0.7× | 20.1% | |
| 7 | ₹25.2k Cr | 50.8× | 37.0% | 28.7% | 26.6% | 1.0× | 0.2× | 12.3% | |
| 8 | ₹18.4k Cr | 64.8× | 19.9% | 28.3% | 11.4% | 1.7× | 0.3× | 155.6% | |
| 9 | ₹16.8k Cr | 63.3× | 2.6% | 24.6% | 10.0% | 2.4× | 0.1× | -32.8% | |
| 10 | ₹16.6k Cr | 154.2× | -13.0% | 18.8% | 5.8% | 1.4× | 0.1× | -40.1% | |
| 11 | ₹9.6k Cr | 73.3× | -8.0% | 31.0% | 26.5% | 0.9× | 0.0× | -1.4% |
Market cap, P/E and the 12-month return move with the market and are dated to the last close. Every other column is the last full financial year. n/m — loss-making, so the multiple means nothing. A dash means not recorded, which is not the same as nil.
| Metric | LAURUSLABS | DIVISLAB |
|---|---|---|
| What you pay6 Nov 2026 | ||
| Share price | ₹2,340.00 | ₹10,320.50 |
| Market cap | ₹1,26,337 Cr | ₹2,74,009 Cr |
| P/E | 94.41× | 92.37× |
| P/B | 23.84× | 16.35× |
| P/S | 18.54× | 25.95× |
| 12-month return | 138.8% | 49.9% |
| SizeFY26 | ||
| Revenue | ₹6,813 Cr | ₹10,560 Cr |
| PAT | ₹889 Cr | ₹2,568 Cr |
| Net worth | ₹5,300 Cr | ₹16,761 Cr |
| Gross block | ₹4,371 Cr | ₹6,528 Cr |
| GrowthFY26 | ||
| Revenue growth | 22.7% | 12.8% |
| Revenue CAGR (3y) | 4.1% | 10.8% |
| PAT CAGR (3y) | 4.0% | 12.1% |
| What it keepsFY26 | ||
| EBITDA margin | 26.2% | 32.6% |
| PAT margin | 13.0% | 24.3% |
| ROCE | 17.8% | 21.5% |
| ROE | 16.8% | 15.3% |
| CFO / PAT (3y) | 2.05× | 0.89× |
| What it owesFY26 | ||
| Net debt | ₹2,405 Cr | ₹-3,407 Cr |
| Debt / equity | 0.43× | 0.00× |
| CWIP | ₹773 Cr | ₹2,113 Cr |
| Debtor days | 115 days | 103 days |
| Who owns itFY26 | ||
| Promoter holding | 27.5% | 51.9% |
| Institutional holding | 42.7% | 39.6% |
Every figure comes from the same filings the company pages are built from. A dash means the figure is not recorded, which is not the same as nil.
Laurus is a CDMO and a maker of generic medicines: it makes APIs, the active ingredients inside medicines, and develops and makes medicines to order for other drug companies. CDMO was 41% of Jul–Sep 2026 revenue and grew 75%; affordable medicines, largely HIV treatments, were the other 59%, with HIV sales flat on a year ago. Fifteen manufacturing sites and 8,126 people.
Divi's makes the active ingredients inside medicines. Half the business supplies generic drug makers at very large scale; the other half is custom synthesis, making patented molecules to order for the companies that invented them. Plants in Andhra Pradesh and Telangana, selling mostly to Europe and America, on half as much revenue again as its nearest listed rival.
It spent ₹864 crore on plants in Apr–Sep 2026 and plans more than ₹3,000 crore across FY27 and FY28. A commercial-scale peptide plant opened in the Jul–Sep quarter with over 16,000 litres of synthesis capacity, a large fermentation plant is due by Oct–Dec 2026, and a tablet plant with KRKA starts validation in mid-2027. It agreed to buy 60% of Galenvs in Canada for oligonucleotides, and plans to buy 52% of SI&C Resins for peptide materials. Fifty-four inspections passed by major regulators, and 92 drug master files filed.
Gross fixed assets rose 20% last year, with three major capital programmes close to finishing and under regulatory validation, and a new site at Kakinada doing backward-integration work while it waits to be qualified for commercial supply. There are no acquisitions and two subsidiaries. Peptides are the main area of investment, with capacity being added in both solid-phase and liquid-phase synthesis.
Founder Dr Satyanarayana Chava runs it, and since April 2024 two more of his family have held executive director seats — his son Krishna Chaitanya Chava runs the CDMO business and his daughter Soumya Chava affordable medicines. The promoter group owns 27.47%, unchanged in the Jul–Sep quarter, and a small parcel of about 0.6% of the company is pledged. In FY26 the founder was paid 491 times the median employee, up 89%, mostly bonus as results improved.
Founder Dr Murali K. Divi remains managing director, his son Dr Kiran S. Divi is chief executive and his daughter Nilima Prasad Divi is commercial director — the three senior operating roles held by one family, which owns 51.88% of the shares. Six independent directors sit alongside them. The family takes ₹224 crore of pay, about 9% of profit, and ₹347 crore of dividend on the stake it owns.
On why it keeps adding new kinds of drugs — “We are investing because our customers are asking. It's not that we are investing, we are liking.”
Dr Satyanarayana Chava · Q2 FY27 earnings call
On customer concentration — “Currently, we don't have a significant concentration of customers or programs.”
Dr Satyanarayana Chava · Q2 FY27 earnings call
Custom synthesis rose sharply in the June quarter — before the three big expansion projects have contributed anything.
Q1 FY27 earnings call
Long-term contracts for iodine-based contrast media are being signed with two customers, one already in commercial supply.
Q1 FY27 earnings call
Closing prices to 6 Nov 2026, adjusted for bonuses and splits. Dividends are not counted. This is what happened, not what will.
A sector, read end to end, and the companies as they are published. Roughly monthly. Nothing else, and one click to stop.